Arnuity Ellipta

  • Asthma/COPD

Arnuity Ellipta Generic Name & Formulations

General Description

Fluticasone furoate 50mcg, 100mcg, 200mcg; per inhalation; dry pwd for oral inhalation.

Pharmacological Class


How Supplied

Dry pwd inhaler—30 doses


Generic Availability


Mechanism of Action

Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti‑inflammatory activity. The precise mechanism through which fluticasone furoate affects asthma symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. These anti-inflammatory actions of corticosteroids may contribute to their efficacy.

Arnuity Ellipta Indications


Maintenance treatment of asthma in patients ≥5yrs.

Limitations of Use

Not for relief of acute bronchospasm.

Arnuity Ellipta Dosage and Administration


Base initial dose on previous asthma therapy and disease severity. Not on inhaled corticosteroid: usually initiate at 100mcg once daily; may increase to 200mcg once daily if inadequate response after 2 weeks. Max 200mcg/day. Rinse mouth after use.


<5yrs: not established. 5–11yrs: 50mcg once daily. Rinse mouth after use.

Arnuity Ellipta Contraindications


Primary treatment of status asthmaticus or acute asthma episodes. Severe hypersensitivity to milk proteins.

Arnuity Ellipta Boxed Warnings

Not Applicable

Arnuity Ellipta Warnings/Precautions


Do not exceed recommended dose. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Immunosuppressed. Tuberculosis. Systemic infections (eg, fungal, bacterial, viral, parasitic). Ocular herpes simplex. If exposed to chickenpox or measles, consider immune globulin or antiviral prophylactic therapies. Monitor for adrenal insufficiency when transferring from systemic steroids. Reevaluate periodically. Monitor for hypercorticism and HPA axis suppression (if occurs, discontinue gradually), growth in children, IOP, glaucoma, or cataracts. Consider eye exams if ocular symptoms develop or in long-term use. Discontinue and treat if paradoxical bronchospasm occurs; use alternative therapy. Assess bone mineral density if risk factors exist (eg, prolonged immobilization, osteoporosis, postmenopausal, tobacco use, advanced age, poor nutrition, others). Moderate or severe hepatic impairment; monitor. Elderly. Labor & delivery. Pregnancy; monitor. Nursing mothers.

Arnuity Ellipta Pharmacokinetics


Peak plasma concentrations: within 0.51 hour.

Absolute bioavailability by inhalation: 13.9%.


Mean volume of distribution at steady state: 661 L.

Plasma protein bound: 99.6%.


  • Hepatic (CYP3A4). 



Half-life: ~24 hours.

Arnuity Ellipta Interactions


Caution with concomitant strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole).

Arnuity Ellipta Adverse Reactions

Adverse Reactions

Nasopharyngitis, upper respiratory tract infection, headache, bronchitis, oral candidiasis; hypersensitivity reactions (discontinue if occurs); children: also pharyngitis, viral infection.

Arnuity Ellipta Clinical Trials

See Literature

Arnuity Ellipta Note

Not Applicable

Arnuity Ellipta Patient Counseling

See Literature